Skip to main content
BAXTER INTERNATIONAL INC logo

BAXTER INTERNATIONAL INC — Investor Relations & Filings

Ticker · BAX ISIN · US0718131099 LEI · J5OIVXX3P24RJRW5CK77 US Manufacturing
Open in API
Filings indexed 2,456 across all filing types
Latest filing 2022-04-07 Director's Dealing
Country US United States of America
Listing US BAX

About BAXTER INTERNATIONAL INC

https://www.baxter.com/

Baxter International Inc. is a global healthcare company focused on saving and sustaining lives. The company provides a broad portfolio of essential products across renal care, hospital, and surgical settings. Key offerings include technologies for acute and chronic dialysis, sterile intravenous (IV) solutions, infusion systems, clinical nutrition, and critical care. Baxter develops, manufactures, and markets a range of medical devices, connected care solutions, and advanced injectable pharmaceuticals. The company's products are used by healthcare professionals in hospitals, clinics, and homes to provide smarter, more personalized care for patients.

Recent filings

Filing Released Lang Actions
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2022-04-07 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2022-04-05 English
DEFR14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'SCHEDULE 14A Proxy Statement' and is an amendment to a previously filed proxy statement for the 2022 Annual Meeting of Stockholders. It discusses voting requirements, broker non-votes, abstentions, and amendments to proposals related to the company's Certificate of Incorporation. The content is focused on proxy solicitation and voting information for shareholders rather than financial results, management changes, or other report types. The presence of 'Proxy Statement' and detailed voting instructions clearly identifies this as a Proxy Solicitation & Information Statement. The document length (7332 characters) and content confirm it is the statement itself, not just an announcement. Therefore, the correct classification is 'DEF 14A' (Remuneration Information) or 'PSI' (Proxy Solicitation & Information Statement). Since this document is a proxy statement amendment and not primarily about remuneration, the best fit is 'PSI'.
2022-03-28 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2022-03-23 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a shareholder alert submitted voluntarily by a shareholder, John Chevedden, regarding voting recommendations on management proposals 4 and 5 related to shareholder rights. It references Rule 14a-6(g)(1) under the Securities Exchange Act of 1934, which pertains to proxy solicitation materials. The content is focused on urging shareholders how to vote on specific proposals and is not a formal proxy statement itself, nor is it a report or announcement of voting results. It is a communication related to proxy solicitation but does not fit the Proxy Solicitation & Information Statement (PSI) category because it is not the official solicitation material but rather a shareholder's commentary. It is also not a Declaration of Voting Results (DVA) or any financial report. Given the nature of the document as a voluntary shareholder communication about proxy voting, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and filings that do not fit other categories. The document length is short (2167 characters), and it is not an official report or announcement of a report publication, so RPA is not appropriate. Therefore, the classification is RNS with high confidence.
2022-03-23 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content discusses responses to FDA information requests related to product applications and anticipated FDA responses, as well as plans for product launch. There are no detailed financial statements or comprehensive financial analysis present. The document is not an earnings release, annual report, or interim report. It is a regulatory announcement about operational updates and regulatory interactions. Given the nature of the filing and its content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2022-03-22 English

Browse filings by year

33 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.